NIFTY 50 23344.75 ▲ (0.61%)
NIFTY NEXT 50 65106.15 ▲ (0.08%)
NIFTY 100 24048.8 ▲ (0.51%)
NIFTY MIDCAP 100 55106.2 ▲ (0.91%)
NIFTY SMALLCAP 100 17864.65 ▲ (1.09%)
NIFTY SMALLCAP 250 16841.4 ▲ (0.84%)
NIFTY MIDCAP SELECT 12356.5 ▲ (0.87%)
NIFTY TOTAL MARKET 12304.6 ▲ (0.6%)
NIFTY BANK 49350.8 ▲ (1.67%)
SENSEX 77073.44 ▲ (0.59%)
BSE BANKEX 56036.23 ▲ (2.03%)

Krebs Biochemicals & Industries : Q4 2024 Financial Quarterly Report : YoY Sales Up 4.47 %, QoQ Down 7.74 %

June 13, 2024June 13, 2024| adminadmin| 0 Comments| 4:15 pm
Image is loading
Categories:

Share the post "Krebs Biochemicals & Industries : Q4 2024 Financial Quarterly Report : YoY Sales Up 4.47 %, QoQ Down 7.74 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 4.47 % in the past year, decrease in net sales/revenue by -7.74 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 10.53 %. Marginal increase in other income during this quarter, up by 600%.
  • Profit over the Year and quarter: Challenges in sustaining profitability for Krebs Biochemicals & Industries Ltd.. Profit dropped by -15.75 % Year to Year, Krebs Biochemicals & Industries Ltd.’s profitability increased by 17.48 % in this quarter.
  • EPS over the Year and quarter: EPS declined by -11.40 % Year to Year. EPS increased by 17.75 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Krebs Biochemicals & Industries Ltd.”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 11.461 Cr Rs. 12.977 Cr Rs. 11.973 Cr -7.74 % + 4.47 %
Expenses Rs. 16.08 Cr Rs. 15.06 Cr Rs. 15.09 Cr + 0.2 % -6.16 %
Operating Profit Rs. -4.62 Cr Rs. -2.08 Cr Rs. -3.12 Cr -50 % + 32.47 %
OPM % -40.31 % -16.03 % -26.06 % -10.03 % + 14.25 %
Other Income Rs. 0.19 Cr Rs. 0.03 Cr Rs. 0.21 Cr + 600 % + 10.53 %
Interest Rs. 1.03 Cr Rs. 1.19 Cr Rs. 1.27 Cr + 6.72 % + 23.3 %
Depreciation Rs. 1.48 Cr Rs. 1.73 Cr Rs. 1.67 Cr -3.47 % + 12.84 %
Profit before tax Rs. -6.94 Cr Rs. -4.97 Cr Rs. -5.85 Cr -17.71 % + 15.71 %
Tax % -0 % -0 % -0 % 0 % 0 %
Net Profit Rs. -6.94 Cr Rs. -4.98 Cr Rs. -5.85 Cr -17.47 % + 15.71 %
EPS in Rs Rs. -3.07 Rs. -2.31 Rs. -2.72 -17.75 % + 11.4 %


Today, we’re looking at Krebs Biochemicals & Industries Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 4.47 %. However, it did see a marginal slip of -7.74 % from the previous quarter. Expenses ticked up slightly by 0.2 % quarter-on-quarter, aligning with the annual decline of -6.16 %. Operating profit, while up 32.47 % compared to last year, faced a quarter-on-quarter dip of -50 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 14.25 %, but a shrinkage of -10.03 % sequentially. Other income rose by 600 % compared to the last quarter, despite an annual growth of 10.53 %. Interest expenses surged remarkably by 6.72 % from the previous quarter, yet the year-over-year increase remains at a moderate 23.3 %. Depreciation costs fell by -3.47 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 12.84 %. Profit before tax grew annually by 15.71 % but saw a reduction from the preceding quarter by -17.71 %.
Net profit rose by 15.71 % year-on-year but witnessed a -17.47 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 11.4 % but a quarterly fall of -17.75 %. In summary, Krebs Biochemicals & Industries Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 11.461 Cr Rs. 12.977 Cr Rs. 11.973 Cr -7.74 % + 4.47 %
Expenses Rs. 16.08 Cr Rs. 15.06 Cr Rs. 15.09 Cr + 0.2 % -6.16 %
Operating Profit Rs. -4.62 Cr Rs. -2.08 Cr Rs. -3.12 Cr -50 % + 32.47 %
Net Profit Rs. -6.94 Cr Rs. -4.98 Cr Rs. -5.85 Cr -17.47 % + 15.71 %
EPS in Rs Rs. -3.07 Rs. -2.31 Rs. -2.72 -17.75 % + 11.4 %


In reviewing Krebs Biochemicals & Industries Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 4.47 % year-on-year growth, although there was a slight dip of -7.74 % from the previous quarter. Expenses decreased by -6.16 % compared to the previous year, with a 0.2 % increase quarter-on-quarter. Operating Profit surged by 32.47 % annually, and saw a -50 % decrease from the last quarter.
Net Profit showed yearly increase of 15.71 %, and experienced a -17.47 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 11.4 % annually, however dipped by -17.75 % compared to the last quarter. In essence, while Krebs Biochemicals & Industries Ltd. exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Krebs Biochemicals & Industries “]

Related Post